338 filings
Page 4 of 17
424B5
7chzv l7e9
31 Jan 12
Prospectus supplement for primary offering
12:00am
424B3
cic0nocp9j997tjw4d
12 Jan 12
Prospectus supplement
12:00am
EFFECT
jyihcvnnj6s zji6
12 Jan 12
Notice of effectiveness
12:00am
CORRESP
8g5qhqp
10 Jan 12
Correspondence with SEC
12:00am
8-K
tz7msm2xjtcp
9 Jan 12
Regulation FD Disclosure
12:00am
UPLOAD
y1ife0tfa mo1nnqq
4 Jan 12
Letter from SEC
12:00am
8-K
pjwa7q
22 Dec 11
Departure of Directors or Certain Officers
12:00am
8-K
ana ijerfpwfe8
19 Dec 11
Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad
12:00am
8-K
it22zzprgocnx
7 Nov 11
Regulation FD Disclosure
12:00am
8-K
jn39t962ssvo5ckcrkq
4 Nov 11
Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results
12:00am
UPLOAD
i5q2p 288rg8
4 Oct 11
Letter from SEC
12:00am
CORRESP
k1zf2yflrgabfbdp
3 Oct 11
Correspondence with SEC
12:00am
UPLOAD
yqz1par9c
19 Sep 11
Letter from SEC
12:00am
CORRESP
eqwceab othaqa1xq35
12 Sep 11
Correspondence with SEC
12:00am
8-K
5muj 6sq4hx17nz
7 Sep 11
Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
12:00am
UPLOAD
ez7 dckl1enyq8hp
26 Aug 11
Letter from SEC
12:00am
S-8
2cde0
26 Aug 11
Registration of securities for employees
12:00am